drugset / Trial / NCT00620607
huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
NaSingle-groupOpen-labelTreatment
Summary
To assess the response rate of huC242-DM4 given as an intravenous infusion to patients with metastatic or locally advanced gastric or gastroesophageal junction cancer.
Timeline
- Start
- 2007-05
- Primary completion
- 2010-05
- Completion
- 2010-09
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CANTUZUMAB RAVTANSINE | Monoclonal antibody | 126 mg/m2 | Intravenous |
| Subject | CANTUZUMAB RAVTANSINE | Monoclonal antibody | 168 mg/m2 | Intravenous |